Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2, Canada
NCT Number: NCT00144092
Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Calgary, Alberta, T2N 4N2, Canada
Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation if they have an HLA matched sibling, or an autologous transplant if they do not.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Alberta Health services
Other
High Dose Chemotherapy and Autologous or Allogeneic Blood Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01300026
Cancer, Chronic Disease
Hackensack, New Jersey, United States
View Trial DetailsNCT00791011
Diffuse Large Cell Lymphoma, Hemic and Lymphatic Diseases
View Trial DetailsNCT03713580
Hemic and Lymphatic Diseases, Immune System Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT01087294
Hematologic Diseases, Hemic and Lymphatic Diseases
Bethesda, Maryland, United States
View Trial Details